![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Elixir Licenses Novel Growth Hormone From Bristol-Myers Squibb
Elixir Licenses Novel Growth Hormone From Bristol-Myers Squibb
April 28, 2005
Elixir Pharmaceuticals announced an exclusive license agreement with Bristol-Myers Squibb Company for worldwide development and commercialization rights to Bristol-Myers Squibb's growth hormone secretagogue (GHS), BMS-604992, and five related compounds. BMS-604992 is a novel, orally available compound that stimulates the body's release of growth hormone.
Yahoo News (http://biz.yahoo.com/bw/050428/285070.html?.v=1)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct